Ayrton Drug Manufacturing Ltd. announced unaudited earnings results for the period ending June 30, 2018. For the period, the company reported revenue of GHS 36,218,331 against GHS 35,016,640 a year ago. Operating profit was GHS 7,152,754 against GHS 4,474,028 a year ago. Profit before tax was GHS 5,233,795 against GHS 3,267,919 a year ago. Profit after tax was GHS 3,615,319 against GHS 2,285,975 a year ago. Profit per share was GHS 0.0168 against GHS 0.0106 a year ago. Net cash flow from operating activities was GHS 1,770,725.13 against net cash flow used in operating activities of GHS 344,702.47 a year ago. Purchase of property, plant and equipment was GHS 645,768.99 against GHS 996,628.14 a year ago.